Skip to main content

Table 4 Incremental total costs of caspofungin and micafungin compared with anidulafungin for each variation of input parameter in a one-way sensitivity analysis

From: Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

Parameter Basecase Change in input lower than base case Change in input higher than base case
Input Incremental costs versus anidulafungina Input Incremental costs versus anidulafungina
Caspofungin Micafungin Caspofungin Micafungin
Anidulafungin drug-acquisition costs (£) £300 per vial −20 % 1252 1068 +20 % 126 −59
Mortality [19] Assumed equivalent 535 287 NA NA NA
Clinical success and mortality [19] Assumed equivalent 316 47 NA NA NA
Clinical success, survive, ICU LOS (days) 11.5 7 1446 1544 14 263 −80
Clinical success, die, ICU LOS (days) 12.8 7 −166 −705 14 868 757
Clinical failure, survive, ICU LOS (days) 19.0 10 968 949 30 349 −37
Clinical failure, die, ICU LOS (days) 20.3 10 151 −241 30 1194 1205
ICU cost per day (£) 1528 1000 544 318 2000 819 672
Time to clinical failure (treatment switch) (days) 3 1 654 482 5 724 527
Clinical failure and die, time to death (days) 7 3 717 543 10 668 475
Clinical success, IV treatment duration (days) 10 7 536 415 14 892 624
  1. ICU intensive care unit; IV intravenous; LOS length of stay; NA not available
  2. aPositive costs indicate that the total cost of the comparator regimen is more expensive than anidulafungin; negative costs indicate that the comparator regimen is less expensive than anidulafungin